Evaluating ctDNA to predict chemotherapy effectiveness in metastatic colorectal cancer
Study on the Efficacy of Chemotherapy for Metastatic Colorectal Cancer Evaluated by Circulating Tumor DNA
This study is testing if measuring tumor DNA in the blood can help predict how well chemotherapy will work for adults with advanced colorectal cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT04555369 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the role of circulating tumor DNA (ctDNA) in predicting the efficacy of chemotherapy for patients with metastatic colorectal cancer (mCRC). By analyzing ctDNA levels, researchers hope to determine how well chemotherapy drugs work in individual patients. The study will include adults aged 18 and older with confirmed advanced colorectal adenocarcinoma and measurable metastatic lesions. Participants will be monitored for their response to treatment based on ctDNA analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced colorectal adenocarcinoma and a life expectancy of at least three months.
Not a fit: Patients with previous chronic inflammatory bowel disease, symptomatic brain metastases, or severe infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective chemotherapy treatments for patients with metastatic colorectal cancer.
How similar studies have performed: Other studies have shown promise in using ctDNA for monitoring treatment response, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status of 0 to 2 life expectancy of ≥ 3 months at least one measurable metastatic lesion have adequate bone marrow, hepatic, and renal function Exclusion Criteria: patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection
Where this trial is running
Shanghai, Shanghai
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Weijian Guo, phD
- Email: iamchangjinjia@163.com
- Phone: 8621-64175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.